APA (7th ed.) Citation

N, B., M, S., Z, C., M, A., Giordano, S., M, C., . . . W, E. (2026). Enhancing the antitumor efficacy using a combination of FGFR4 Inhibitor (H3B-6527) and oxaliplatin in gastric cancer. Neoplasia (New York, N.Y.), 71, 101257. https://doi.org/10.1016/j.neo.2025.101257

Chicago Style (17th ed.) Citation

N, Bhat, et al. "Enhancing the Antitumor Efficacy Using a Combination of FGFR4 Inhibitor (H3B-6527) and Oxaliplatin in Gastric Cancer." Neoplasia (New York, N.Y.) 71 (2026): 101257. https://doi.org/10.1016/j.neo.2025.101257.

MLA (9th ed.) Citation

N, Bhat, et al. "Enhancing the Antitumor Efficacy Using a Combination of FGFR4 Inhibitor (H3B-6527) and Oxaliplatin in Gastric Cancer." Neoplasia (New York, N.Y.), vol. 71, 2026, p. 101257, https://doi.org/10.1016/j.neo.2025.101257.